Junshi narrows its losses but delivers no cure for share price woes
The drug maker boosted sales of its core anti-cancer product in the first half of the year and reined in its research budget under a reform-minded CEO, but revenue momentum…
Innovent Bio hopes for plus-sized profits from obesity drug
The biopharmaceutical company reported a surge in half-year revenues but logged a bigger net loss, as investors look ahead to the launch of its new weight-loss drug Key Takeaways: Sales…
Recent Articles
RELATED ARTICLES
-
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
1877.HK 688180.SHG -
Junshi hopes new scientist CEO can cure its woes
1877.HK 688180.SHG
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK
-
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
